Abstract
Atazanavir (ATV) is an antiretroviral drug of the protease inhibitor class. Multiple adverse effects of ATV have been reported in clinical practice, such as jaundice, nausea, abdominal pain, and headache. The exact mechanisms of ATV-related adverse effects are unknown. It is generally accepted that a predominant pathway of drug-induced toxicity is through the generation of reactive metabolites. Our current study was designed to explore reactive metabolites of ATV. We used a metabolomic approach to profile ATV metabolism in mice and human liver microsomes. We identified 5 known and 13 novel ATV metabolites. Three potential reactive metabolites were detected and characterized for the first time: one aromatic aldehyde, one α-hydroxyaldehyde, and one hydrazine. These potential reactive metabolites were primarily generated by CYP3A. Our results provide a clue for studies on ATV-related adverse effects from the aspect of metabolic activation. Further studies are suggested to illustrate the impact of these potential reactive metabolites on ATV-related adverse effects.
Footnotes
This work was supported by the National Institutes of Health National Center for Research Resources [Grant COBRE 5P20-RR021940].
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.110.036327.
↵ The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- ATV
- atazanavir
- PI
- protease inhibitor
- HIV
- human immunodeficiency virus
- RTV
- ritonavir
- HLM
- human liver microsomes
- P450
- cytochrome P450
- INH
- isoniazid
- KCZ
- ketoconazole
- rcf
- relative centrifugal forces
- UPLC
- ultraperformance liquid chromatography
- TOFMS
- time-of-flight mass spectrometry
- PBS
- phosphate-buffered saline
- PCA
- principal component analysis
- OPLS-DA
- orthogonal projection to latent structures-discriminant analysis
- MS/MS
- tandem mass spectrometry
- TB
- tuberculosis.
- Received September 9, 2010.
- Accepted December 9, 2010.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|